# Research Idea Ranking

**Generated:** 2026-01-30T12:00:25.619298
**Model:** gpt-5.2 (reasoning: high)
**Tokens:** 6297
**OpenAI Response ID:** resp_0c17ab0598e014d800697c72ce85b4819cb37c4cfe39c02f9f

---

### Rankings

**#1: State Data Privacy Laws and Technology Sector Business Formation (REVISED)**
- **Score: 68/100**
- **Strengths:** Very new policy margin (2023–2024 effective-date wave) with plausible, immediate cost channels for data-intensive startups; monthly BFS-style outcomes allow tight timing alignment and event-study diagnostics. Policymakers actively debating these laws would care about entry effects.
- **Concerns:** Identification is only “okay” unless you can rule out tech-sector-specific shocks and policy endogeneity (states may adopt because their tech sectors are large/growing). Also, statutory thresholds/exemptions mean many “Information” startups may not be treated, risking attenuation.
- **Novelty Assessment:** **High.** There are papers on privacy regulation broadly, but the **recent U.S. state comprehensive privacy-law wave** and **business formation by sector** is still comparatively under-studied; likely not “100 papers already.”
- **DiD Assessment (Callaway–Sant’Anna on 2023+ cohort):**
  - **Pre-treatment periods:** **Marginal** (you propose 2020–2022 only = 3 years; better if you can credibly add 2015–2019 and model COVID explicitly)
  - **Selection into treatment:** **Marginal** (adoption plausibly political, but also correlated with tech intensity and underlying trends)
  - **Comparison group:** **Strong/Marginal** (many never-treated states exist, but treated states are systematically more tech-oriented; needs balancing / covariate adjustment and strong pre-trend evidence)
  - **Treatment clusters:** **Marginal** (≈10 treated states in the clean cohort; inference can be fragile—use wild cluster bootstrap / randomization inference)
  - **Concurrent policies:** **Marginal** (other contemporaneous “tech” policies—AI rules, platform regulation, broadband initiatives, tax incentives—could move entry)
  - **Outcome-Policy Alignment:** **Strong/Marginal** (NAICS 51 is closer than broad aggregates, but privacy laws apply economy-wide and thresholds exempt many small firms; consider outcomes more directly tied to covered entities if possible)
  - **Data-Outcome Timing:** **Strong** (state-month data; can code treatment at the effective month—e.g., July 1 effective → July onward treated; can also drop partial-exposure months as a robustness)
  - **Outcome Dilution:** **Marginal/Weak** (many NAICS 51 applicants will be too small to meet coverage thresholds—could be <20% “treated”; mitigate by focusing on measures more indicative of scale—e.g., corporate/high-propensity apps, or later outcomes like QCEW establishment counts/employment)
- **Recommendation:** **PURSUE (conditional on: extending pre-periods to ≥5 years or presenting a compelling COVID-handling strategy; demonstrating strong pre-trends/event-study balance; addressing dilution via outcomes more tied to covered firms and/or heterogeneity by firm type/state thresholds)**

---

**#2: State PBM Spread Pricing Bans and Pharmacy Closures**
- **Score: 47/100**
- **Strengths:** Clear policy relevance (rural pharmacy access) and a plausible mechanism (spread pricing affects reimbursement margins, especially in Medicaid managed care). If you can build a credible “strong ban” definition and timing, the question is valuable.
- **Concerns:** High risk of **policy endogeneity** (states often act after closures/financial distress), major **concurrent policy changes** in pharmacy reimbursement, and substantial heterogeneity across PBM laws. State-year CBP counts are a blunt outcome and may not map cleanly to independent-pharmacy viability.
- **Novelty Assessment:** **Medium.** PBMs are widely studied in health economics and policy, but **causal evidence specifically linking spread-pricing bans to pharmacy closures** is not yet saturated; still, there is related literature on PBM regulation and pharmacy margins.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (CBP exists well before 2017, so you can assemble long pre-trends)
  - **Selection into treatment:** **Weak** (likely adopted in response to pharmacy distress/closures and political pressure—classic “responding to trends” risk)
  - **Comparison group:** **Marginal/Weak** (few truly “clean” never-treated states; many states have partial PBM reforms → contaminated controls)
  - **Treatment clusters:** **Marginal** (depends on strictness; true “spread pricing ban” states may be <10–15 in a clean window)
  - **Concurrent policies:** **Weak** (dispensing fee changes, reimbursement floors, 340B protections, Medicaid MCO contracting reforms often coincide and directly affect closures)
  - **Outcome-Policy Alignment:** **Strong/Marginal** (pharmacy counts/employment reflect market exits, but “spread pricing bans” often apply primarily to Medicaid managed care—closure is an indirect outcome)
  - **Data-Outcome Timing:** **Marginal** (CBP is tied to a March pay-period snapshot; laws often effective mid-year—need to code first *full* post year and be explicit)
  - **Outcome Dilution:** **Marginal/Weak** (if policy mainly affects Medicaid payments, only a fraction of pharmacy revenue is treated; dilution could be substantial at the state level)
- **Recommendation:** **SKIP (unless you can: (i) find a sharper, plausibly exogenous trigger—e.g., court orders/contracting mandates; (ii) use more directly targeted data like NCPDP pharmacy openings/closures or claims-based measures; and (iii) isolate Medicaid-specific exposure and concurrent reimbursement reforms).**

---

**#3: State Autonomous Vehicle Laws and Traffic Safety**
- **Score: 39/100**
- **Strengths:** Interesting and policy-salient question; FARS is high-quality and universally available, and staggered adoption provides variation on paper.
- **Concerns:** The core problem is **outcome dilution**: AV testing/operation authorization does not imply meaningful AV penetration in statewide VMT during most of the sample, so any true effect on statewide fatality rates is likely mechanically near zero. Also, “AV law” is a noisy proxy for actual exposure (deployment), undermining interpretation.
- **Novelty Assessment:** **Medium-High.** There is a large traffic safety policy literature, but fewer clean causal papers on **state AV enabling legislation** and fatalities specifically; the topic is newer than many transportation policies.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (2005–2010 gives ≥5 years pre for earliest adopters; later adopters have more)
  - **Selection into treatment:** **Marginal** (early adopters are distinctive—tech-forward states/cities; could correlate with safety trends and urbanization)
  - **Comparison group:** **Marginal** (never-treated states may differ systematically; also “implicit permission” via DMV actions may contaminate controls)
  - **Treatment clusters:** **Strong** (≈29 treated states over time)
  - **Concurrent policies:** **Marginal** (many coincident road safety, distracted driving, DUI, and infrastructure policies move fatalities)
  - **Outcome-Policy Alignment:** **Marginal** (fatalities are the right *ultimate* outcome, but AV *legislation* is a weak proxy for AV exposure)
  - **Data-Outcome Timing:** **Marginal** (annual outcomes vs mid-year effective dates—must code treatment as beginning the first full calendar year after effectiveness to avoid partial exposure)
  - **Outcome Dilution:** **Weak** (AV share of VMT is far below 10% for most of the period; likely <1% → statewide fatality rates barely move even if AVs are safer)
- **Recommendation:** **SKIP (unless you can obtain a high-exposure outcome or setting—e.g., city/county crash data where AV miles are concentrated, or crashes involving ADS-equipped vehicles; otherwise the design is almost guaranteed to produce uninterpretable nulls).**

---

### Summary

Only **Idea 2** clears the bar as a credible, policy-relevant project, but it is still **conditional** on strengthening pre-trends, inference with only ~10 treated states, and (crucially) mitigating **treatment dilution from coverage thresholds**. **Ideas 1 and 3 fail the DiD checklist on critical criteria** (Idea 1: outcome dilution; Idea 3: selection into treatment and concurrent policies), making null or ambiguous findings highly likely without major redesign.